Bio3DPrinting introduces the first 3D bioprinter to clinical laboratories

Barberino Tavarnelle (FI) / Treviso, October 27, 2023 - SolidWorld GROUP, through its subsidiary Bio3DPrinting, today gave the world its first look at “Electrospider“, the first patented 3D bioprinter capable of reproducing human cell tissues.

Electrospider’s groundbreaking objective is to create complex implantable human organ structures, representing a breakthrough in technological progress for the benefit of human life. This innovation will enable the study of complex multicellular tissue samples obtained from patients’ cells, without the need for direct tests on those patients.

«We are excited and proud to officially introduce Electrospider to the Italian medical industry. This innovative technology constitutes a major breakthrough in human tissue reproduction and clinical trials. We therefore look forward to seeing how Electrospider's innovative qualities will help improve medical research and patient quality of life. This is certainly a major breakthrough in regenerative medicine and biofabrication. It combines the most advanced 3D technology of generating the digital twin of a complex tissue or organ with the innovation of creating a biological twin of that tissue or organ.» Roberto Rizzo, Solidworld GROUP President

The history of Electrospider

Developed entirely in Italy by Bio3DPrinting, Electrospider is the world’s only additive manufacturing solution that can reproduce tissue parts and cellular constructs for organic structures. It is ideal to support research in areas such as cosmetics, pharmacology, oncology, vaccine development, treatments for genetic diseases, and pre-operative reconstructive surgery.

This revolutionary machine is the brainchild of Professor Giovanni Vozzi, an expert in electronic and computer bioengineering at the University of Pisa, who patented the system globally. Bio3DPrinting then assumed the role of a spin-off within the University of Pisa, creating the first 3D bioprinter model, later presented at the Montecatini Biofabrication Congress in 2022.

Thanks to its spider-shaped extrusion system, Electrospider can today deposit organic material on the print bed, replicating the process of a common 3D printer. Layer by layer, the bioprinter creates portions of “living” human tissue, developed from cells cultured in vitro and taken directly from patients or donors. This greatly reduces the waiting time for implantable materials and the risks of rejection, enabling in-depth analysis of samples collected for research in a variety of fields.

Electrospider represents a significant step forward in the evolution of medical technology, promising significant advances in regenerative medicine and medical treatments.